Ofloxacin

Evidence Level: L5

Predicted Indications: 10

Ofloxacin

Pharmacist Assessment Report

Ofloxacin: From Bacterial Infections to Polyclonal Hyperviscosity Syndrome

One-Sentence Summary

Ofloxacin is a fluoroquinolone antibiotic originally used for infections such as typhoid fever, urinary tract infection, bronchitis, and bacterial pneumonia. The TxGNN model’s top-ranked predictions are mostly unrelated to infection, so this report focuses on the best-supported candidate, Septicemic Plague, which has 0 clinical trials and 11 publications (all preclinical or laboratory studies). Among the top 10 predictions, only septicemic plague has a biologically coherent rationale and a meaningful body of supporting literature.

Quick Overview

Item	Content
Original Indication	Typhoid fever, salmonellosis, urinary tract infection, bronchitis, bacterial pneumonia, and other bacterial infections (the Canadian licence record has no indication text)
Predicted New Indication	Septicemic plague (rank 8 of the top 10 predictions; selected as the most plausible). The rank 1 prediction is polyclonal hyperviscosity syndrome.
TxGNN Prediction Score	0.9979 (septicemic plague); 0.9991 (rank 1, polyclonal hyperviscosity syndrome)
Evidence Level	L5 (preclinical studies only) for septicemic plague; L5 for the rank 1 prediction
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Recommended Decision	Hold (research question only; not ready to proceed)

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Ofloxacin is a fluoroquinolone, a class known to inhibit bacterial DNA gyrase and topoisomerase IV, and its efficacy in a range of bacterial infections is established.

Plague is caused by Yersinia pestis, a Gram-negative bacterium that is susceptible to this mechanism. The extension from the original indications to plague is therefore a broadening of the antibacterial spectrum rather than a new mechanism. Laboratory studies show ofloxacin is highly active against Y. pestis isolates, and mouse studies show activity in experimental plague.

By contrast, most of the higher-scoring predictions (polyclonal hyperviscosity syndrome, hyperamylasemia, congenital analbuminemia, premalignant and congenital haematological disorders, and monoclonal gammopathy) have no identifiable link to an antibacterial mechanism. Their high scores reflect network-based model output only, with no supporting trials or literature. Hematological disease associated with acquired peripheral neuropathy is a particular concern, since fluoroquinolones can themselves cause peripheral neuropathy. Punctate epithelial keratoconjunctivitis has only a weak indirect link: ofloxacin is used in eye infections, but this condition is often viral or inflammatory, and the single retrieved paper is not an ofloxacin efficacy study.

Clinical Trial Evidence

Currently no related clinical trials registered for septicemic plague or any of the other top 10 predicted indications.

Literature Evidence

All studies below concern septicemic plague. No human trials were found. Types are limited to animal and in vitro work.

PMID	Year	Type	Journal	Key Findings
16127904	2002	Animal study	Antibiot Khimioter	Ofloxacin showed in vitro activity against Y. pestis (MIC 0.08 mg/L) and was tested for prophylaxis and treatment in mice. It was less effective against strains lacking fraction I and mouse toxin.
9517950	1998	Animal study	Antimicrob Agents Chemother	Mouse model of pneumonic plague used to compare antibiotics against streptomycin.
8203841	1994	Animal study	Antimicrob Agents Chemother	Ofloxacin was active in vitro and was compared with beta-lactams, aminoglycosides, and doxycycline in a mouse model of systemic Y. pestis infection.
11871319	2001	Animal study	Antibiot Khimioter	Experimental bubonic plague model in baboons developed to evaluate antibacterials.
10987101	2000	Animal study	Antibiot Khimioter	Fluoroquinolones including ofloxacin reduced vaccine-induced immunity in mice, which matters for combined emergency prophylaxis and vaccination.
8540736	1995	In vitro	Antimicrob Agents Chemother	Among 14 agents tested on 78 Y. pestis strains, ceftriaxone and ciprofloxacin were most active, followed by ofloxacin and ampicillin.
8913481	1996	In vitro	Antimicrob Agents Chemother	Ofloxacin and levofloxacin were highly active against 100 human isolates (MIC90 below 0.03 µg/ml).
18644132	2008	In vitro / molecular	BMC Microbiol	Screening for genes that may reduce antibiotic susceptibility in Y. pestis.
13677133	2003	In vitro	Antibiot Khimioter	Formation of plague mutants resistant to rifampicin and quinolones.

Two further retrieved papers (PMIDs 19121669 and 12180019) concern fluoroquinolone resistance in Burkholderia pseudomallei, and one (PMID 11057367) concerns Vibrio cholerae. They are off-target organisms and do not support the plague indication.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02143291	OCUFLOX	Not specified	Not specified

The product name suggests an ophthalmic formulation. This has not been confirmed, and the available data do not specify a dosage form or route. Whether it can be used for systemic infections such as plague is therefore unknown.

Safety Considerations

Contraindication signals from the knowledge graph (these are database associations, not label text):

Cardiac: long QT syndrome (including familial), torsades de pointes
Neurological and neuromuscular: epilepsy, myasthenia gravis (including adult-onset), neuromuscular junction disease, peripheral neuropathy, peripheral nervous system disease
Tendon and musculoskeletal: tendinitis, periarthritis, rhabdomyolysis
Hepatic and renal: liver failure, liver disease, drug-induced liver injury, kidney disease, impaired renal function
Metabolic: diabetes mellitus, diabetic ketoacidosis, potassium deficiency
Haematological: thrombocytopenia, leukopenia, anaemia
Gastrointestinal: Clostridium difficile colitis

Drug Interactions: 100 interactions were identified in total. Interactions rated Major among those listed include:

Corticosteroids: hydrocortisone, triamcinolone, dexamethasone, betamethasone
Bupropion
Chlorpropamide

Moderate interactions include:

Antidiabetic agents (acarbose, alogliptin, metformin, pioglitazone, canagliflozin, albiglutide)
Famotidine
Loperamide
Aspirin
Balsalazide
Bisacodyl
Calcium and potassium salts (calcium phosphate, calcium acetate, potassium citrate)

Blood glucose monitoring is relevant with antidiabetic agents. Combining with corticosteroids is relevant to the tendon-related signals above.

Please refer to the package insert for label warnings and contraindications. Those were not available for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The highest-scoring predictions are unsupported by any trial or literature and have no plausible mechanism, so they should not be pursued. Septicemic plague is biologically coherent and has consistent in vitro and animal data (L4), but there are no human trials. It also falls within ofloxacin’s existing antibacterial spectrum, and the only Canadian licence in the data appears to be an ophthalmic product. This makes it a research question rather than a candidate ready to advance.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
Mechanism of action data from DrugBank
Confirmation of the dosage form and route for the Canadian licence, and whether a systemic formulation is available
Comparison with current plague guidelines, in which other fluoroquinolones and agents are already established, and any human clinical data
Review of the QT, tendon, neuropathy, and drug interaction signals for the intended population
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.